Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

Last week Tuesday, PureTech had announced that Raju Kucherlapati stepped down immediately as chair and was replaced by Sharon Barber-Lui, who will be interim chair and also lead the process for ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis ...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...